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Abstract: The incident of non-melanoma skin cancer and keloid is increasing and is associated with pain, itch and 
discomfort. Several methods have been used for the treatment but are associated with high recurrence rate. Tailor made 
Rhenium-188 (188Re) skin patch is convenient, non-invasive and safe method for the treatment. The recurrence is not 
noted during follow up period of more than three years. 
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INTRODUCTION 
The skin is in direct contact with the atmosphere 
and its changes. The exposure to UV radiation, 
particularly the UV-B is responsible for non-melanoma 
skin cancer: basal cell carcinoma (BCC), squamous 
cell (SCC) and represents approximately 95% of all 
skin cancers [1]. However, some artificial sources of 
sunlight like tanning booths, sunlamps may also cause 
skin cancer. BCC is painless, shiny raised area with 
ulcer, usually non-metastatic but is life-threatening if 
becomes metastatic [2]. SCC usually presents as a 
hard lump with a scaly cover. However, it may also be 
ulcerative. SCC can often be metastatic [3].  
Keloids are benign dermal fibro proliferative scars 
developed during the process of healing at the site of 
surgery or trauma. The Keloids develop in humans 
only; however the incident in male and female genders 
is equal. But the incident is more in the individuals or 
races with high skin pigmentation. These can be 
formed in due course after the injury (>1 year) and 
often enlarge beyond the original scar margins. The 
most common sites for keloid are high skin tension 
areas that include anterior chest and neck, deltoid 
region and shoulders [4]. Pain and pruritus are the 
common complaints in patients bearing keloids. 
MANAGEMENT 
Skin cancers and keloid are managed in a similar 
way. Several treatment options are available. In 
general, the patients were informed about the available 
treatment options and related problems. Based on the 
choice of patients the therapies are given.  
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Invasive Therapies 
Surgical resection is curative and the choice of 
treatment for BCC and SCC. The surgical excision of 
lesion along with an adequate margin has high cure 
rate. The lesions often recommended for surgery are 
nodular, well delineated with tumor size up to 4 cm. For 
aggressive tumors, the excision beyond the margins 
(usually 1 cm) is also considered. Mohs’ micrographic 
surgery is the best choice and consists of real-time and 
progressive histological examination of tissue to 
evaluate the extent of tumor (the gold standard for 
diagnosis of cancer tissue). This helps in preserving 
the healthy tissue [5]. This procedure is tedious and 
expensive, therefore recommended for patients with 
special criteria. These patients include young, large 
tumor size, immuno-compromised, indistinct tumor 
margins, tumor originated in burns, histologically 
proven recurrent and aggressive etc [6, 7]. High 
success rate of Mohs’ micrographic surgery (>90%) 
has been reported for BCC, and SCC [8].  
The areas where surgical excision is not possible 
either due to location (ear, eyelids, nose) or if the lesion 
is large and healthy tissue is not sufficient for sutures, 
plastics reconstruction surgery is often recommended. 
However relapse in these lesions is difficult to manage. 
The relapse may also occur in patients with keloids as 
the skin has the tendency to develop keloid at surgery 
or trauma site. In both conditions, a combinational 
therapy i.e. surgery with radiotherapy or radionuclide 
therapy, is preferred for better outcome. 
Local therapies 
The laser therapy eliminates excessive 
inflammatory and cancerous tissue either by inducing 
collagen shrinkage or inhibiting the production of 
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collagen, microvascular thrombosis and by selectively 
inhibiting the metabolism [9-12]. The mechanical 
compression therapy using silicone gel, silicone 
occlusive dressings results in reduction of tissue 
metabolism, fibroblast proliferation and scar regression 
[13]. The photodynamic therapy is done using tumor-
localizing photosensitizing agents like 5-amino-livulinic 
acid and methylaminolaevulinate followed by activation 
with visible light. These agents may be transported via 
Na+/Cl- dependent cell membrane activity or via active 
or passive transmembrane diffusion selectively by 
hyper-proliferative cells and cause cell death by variety 
of biochemical pathways. Photosentitizers mixed with 
liposomes are also used to improve the transmem- 
brane delivery [14]. The photodynamic therapy is less 
efficacious for the treatment of SCC. The recurrence 
rate is also high (~50%) [15-21]. The cryo-therapy 
using liquid nitrogen is to freeze the cancerous cells 
and collagen tissue followed by cell anoxia. This 
procedure is often repeated and may also be used in 
combination with intra-regional steroids administered 
for better outcome [9-12]. However, relapse due to the 
presence of tumor in the margins on histopathology, 
hyperpigmentation, pain, edema and blistering has 
been reported as adverse events [22]. The topical 
therapies are also been used for the treatment of keloid 
and tumors located in critical or inoperable patients e.g. 
patients with systemic underlying diseases like 
cardiomyopathy and pulmonary insufficiency. These 
include an immune response modifier, imiquimod  
[16-18]. Interferon therapy is done either by inducing 
the production of local interferon (verapamil, 
cyclosporine, D-penicillamine, retinoic acid, topical 
zinc, etc [23, 24] or by intralesional injection of 
interferons into the papillary dermis or into the fresh 
lesion to inhibit collagenase activity using drugs like 
tamoxifen, 5-fluorouracil alone or in combination 
excision until the disappearance of lesions [25-28]. 
These therapies often lead to development of 
hypopigmentation, pain, edema, blistering, dyschromia, 
scaring in treated lesions. Moreover, all these therapies 
are beneficial for lesions smaller in size and with non-
recurrent histology. 
Radiotherapy 
Radiotherapy is associated with cell killing by DNA 
damage. It includes electron beam, X-rays, neutron 
beam and brachytherapy. The external radiation 
therapy is a non-invasive procedure but is associated 
with risk involving long-term cosmetic problems and the 
high recurrence rate. The therapy is beneficial in 
patients when surgical intervention is contraindicated. 
Superficial irradiation or orthovoltage X-rays are used 
for the treatment [29]. Erythema, pigmentation, and 
moist reaction may occur as acute radiation effects 
however epidermal atrophy, scaling, pigmentation, 
fibrosis, and necrosis are some chronic effects [30-31]. 
This treatment is not recommended where penetrating 
radiations can be harmful (e.g face, eyes). There are 
disadvantages like cost, frequent and repeated visit to 
hospital. The special care is to be taken for the 
fractionation of dosage to protect underlying organs. 
Radioactive Skin Patch 
The Beta (β) particles have high linear energy 
transfer (LET), and rapid fall of. This unique property 
allows localized radiation to the superficial skin lesions 
and spares the underlying soft tissue and bone when 
treated with radioactive skin patch. Moreover, the 
procedure is non-invasive, painless, low cost and 
patient convenient. The surgical excision in 
combination with high-dose patch therapy is highly 
recommended [32]. The pure beta (β) or beta/gamma 
(β/γ) emitters are used as the sources of radiation for 
the treatment [33-36]. Different radionuclides and patch 
materials have been used for patch preparation  
[37-41]. 
The patch, a tailor made radiation source, is 
prepared incorporating radioactive beta-emitting 
isotopes on the inert matrix. The source is applied on 
the surface of the lesion to limit irradiation to the area 
and depth affected by the tumor / keloid. The 
radioactivity is spread uniformly on to the matrix and 
the patch prepared is laminated to prevent direct 
contact with skin. The patch containing the radiation 
source can easily adapt to skin surface without 
contamination. The dose is delivered to lesion and 
spares the healthy tissue. The therapy can be used for 
large sized lesions, relapsing or recurrent lesions and 
also for multifocal lesions. The treatments can be 
performed as a day care procedure in the Nuclear 
Medicine Department. The tailor made radioactive 
patch can be applied superficially on the lesion to treat 
skin diseases like basal cell carcinoma, SCC and 
keloids.  
Tailor Made 188Re Patch: Technical Considerations 
The patches and creams prepared with Re-188 for 
the treatment of skin cancers in animal model are 
reported in the literature [42-44]. Re-188 isotope is 
generator produced β/γ emitter with maximum ß 
energy (Eßmax) 2.12 MeV, Eßavg 764 keV and half-life is 
16.9 h. The γ-photon energy is 155 keV (15%) that 
allows the accurate measurement of activity to 
incorporate on the patch. The W-188/Re-188 generator 
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is commercially available for clinical use. The high-
energy ß-particles of 188Re are effective at short range 
and more than 90% is deposited in 2-3 mm therefore 
spare healthy tissue irradiation unlike external beam 
radiotherapy. The availability of generator offers the 
ease to use the isotope on routine basis; hence the 
therapy can easily be planned. 
Patch Preparation 
188Re tin colloid is prepared by the method 
described earlier [45]. 188Re perrhenate is freshly 
eluted from W-188/Re-188 generator. 188Re colloid is 
prepared by dissolving dihydrated SnCl2 in dilHCl and 
mixing with freshly eluted 188Re. The solution is heated 
for 90 min at 100oC on water bath followed by cooling 
to room temperature and centrifugation. The pellet is 
separated and resuspended in required volume. 188Re 
colloid (1mCi/cm2) is uniformly spread onto the 
cellulose based paper (3 mm) on pre-cut 1cm*1cm 
patch and dried. The patch is laminated with water 
proof adhesive plaster. Prepared patch is exposed to 
radiochromic film and also imaged under gamma-
camera to study the distribution of radioactivity on the 
patch. Images are processed and regions of interest 
(ROIs) are drawn to record counts and determine the 
distribution of total counts across various regions on 
patch as shown by patterns in Figure 1 (a-d). The 
exposure on the surface of the patch and at one meter 
distance in vertical direction are observed to see the 
radiation exposure to public.  
Dose Calculation 
Radiochromic, Gafchromic film EBT3 film, is used 
for high dose radiation dosimetry for beta and gamma 
rays, to determine the dose delivered to the surface of 
skin and the penetration depth of 188Re. A Calibration 
curve between dose (up to 40 Gy) and the CT Number 
is plotted using standard clinical 6 MeV electron beam 
of medical linear accelerator, present in radiotherapy 
department. The calibration curve follows linear relation 
with the equation: 
y = 46.2x + 326.3 
where, y is CT number (a quantitative scale for 
describing radiodensity) and x is dose. 
The unknown dose from 188Re patch (1 cm*1 cm) 
containing 37 MBq(1mCi) is exposed to radiochromic 
film for one hour, by putting it in contact with the film, 
and the autoradiograph is evaluated after 24 hours of 
irradiation (Figure 1). The total exposure (dose) to the 
lesion is calculated on the basis of activity and area of 
the patch. The observed CT Number and the dose are 
1811 and 32.14 Gy/hr, respectively. The calculated 
dose for the patch is expressed in Table 1 
Table 1: Estimation of Dose from 1 cm2 Patch Source 
Time Decay Factor Dose (Gy)  
1 hour 1 32.14±1.6 
3 hour 0.884 85.23±4.26 
2nd day (3 h) 0.37 35.67±1.78 (3 h) 
3rd day (3 h) 0.1397 13.47±0.67 (3 h) 
 
The dose delivered by 1mCi/ cm2 patch is 
approximately 100 Gy when exposed for 3 hours, twice 
i.e. at 48 hour interval (day-1 and day-3).The mass 
stopping power of the gafchromic film is approximately 
equal in the wide energy range electrons energies [46]. 
The mass collision stopping power of 6 MeV electron 
beam is 1.87 MeV.cm2.g-1for gafchromic sensor e and 
for average energy Eavg, β= 0.7643 MeV of Re-188 is 
1.86071 MeV.cm2.g-1. Hence the energy correction 
factor is approximately 1. 
Subsequent to the evaluation by a dermatologist, 
the skin cancer and keloid patients are worked up by a 
Nuclear Medicine physician. Histopathology of skin 
cancer is mandatory before therapy. An informed and 
written consent is obtained before therapy. Patients are 
treated on the basis of our pre standardized activity of 
Re-188 per unit area. These are i) 1mCi/cm2 for skin 
cancers, thick and old keloids ii) 0.50 mCi/cm2 for 
newly formed and small keloids iii) 0.75mCi/cm2 for all 
other keloid.  
Customized Patch Preparation and Application 
The clinical photograph of the lesion (keloid/ 
cancer), selected for the treatment, is taken before the 
start of treatment. For preparation of customised patch 
of exact shape of the lesion, area and dose calculation, 
a trace of the lesion is drawn on a transparent sheet. 
The paper trace of the lesion is cut and the same trace 
is replicated on graph paper for area calculation by 
counting the squares inside the trace and also on 
cellulose based absorbent paper for the preparation of 
fit to size patch (Figure 1e). For normal keloid patch 
used is just fit to size. However, for aggressive keloid, 
BCC and SCC, a border of few mm (2-3 mm) beyond 
the lesion is usually included for irradiation. The 
orientation of the patch is to be marked carefully before 
spreading the 188Re colloid. The patch bearing 188Re 
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colloid is dried and laminated with water proof 
transparent adhesive tape in order to prevent the direct 
contact of radioactive matrix with the skin surface 
(epidermis). The exposure above the patch surface and 
at one meter has to be recorded. 
 
Figure 1 Standardization and preparation of tailor made 
188Re skin patch for therapy. 
(a) Image of patch 1*1 cm, showing distribution of 
radioactivity exposed to radiochromic film. 
(b) Gamma camera image of patch showing distribution of 
radioactivity; total mean counts = 44743. 
(c) Region of interests (ROI) showing count-distribution on 
Re-188 patch, average counts in R=21915, average counts in 
L=21288. 
(d) Region of interests (ROI) showing count-distribution on 
Re-188 patch average counts in U=22465, Average counts in 
D=23249. 
(e) Preparation of patch 1) trace of keloid 2) area calculation 
on graph paper 3) Re-188 patch ready for application. 
(f) Tailor made patch applied on the keloid. 
Patient Preparations  
Before the patch application, cleaning of the lesion 
is required. For SCC and BCC, cleaning includes 
elimination of all the keratinic crusts, granulation tissue 
and scabs to improve the efficacy of the treatment as 
the penetration path of beta particles are short. Sterile 
saline may be used for cleaning. Local anaesthesia, if 
required, is also advisable before cleaning and 
haemostatic agent is to be used on the bleeding 
lesions before patch application. Hair around the lesion 
has to be removed before application of patch. 
Patch Application and Follow Up 
The customized 188Re patch is applied on the lesion 
with adhesive tape (micro pore) for three hrs on day 1. 
The patch is removed, stored safely to be reapplied on 
the same lesion after 48 h (day-3) for three hrs. The 
patient is asked to wears a pair of covered 
spectacles/goggles made of plastic material if the 
treatment is given near the eye. To assess the 
contamination on the lesion, a radioactivity test may be 
performed on the treated lesions. The post therapy 
follow up is done at interval of 1, 3, 6 months and then 
yearly. 
Post Therapy Observation 
Faint redness on the treated area is seen just after 
the treatment and can persist for few days. In some 
patients serum (BCC) or pale yellow discharge (keloid) 
is visualized followed by crust or scab formation. The 
bleeding, if present before the therapy, stops and 
symptomatic relief in pain and itch is experienced by 
the patients. Decolouration of skin can appear (light 
burn) but subsides with time. Clinical healing is usually 
observed within 3 months (90 days) time. Repeat 
histopathology in BCC and SCC patients is required to 
evaluate and confirm the response. 
We have treated only 2 BCC patients and 15 keloid 
patients. In most of the keloid lesions, more than one 
treatment on the same lesions has also been given for 
complete healing. The reason for the need of the 
repeat therapy is the presence of old and thick keloid 
lesions and low penetration of β particles. No adverse 
events have been recorded after patch therapy. All 
patients experienced relief in symptoms like pain, 
ulceration and pruritus after therapy. The reduction in 
size and elevation is noted in all keloid lesions and 
disappearance of the lesion in case of BCC (Figures 2, 
3). The complete flattening of lesion is often observed 
in the newly formed and small keloid lesions after first 
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therapy. The patch therapy may be repeated after 3 
months and separate lesions in same individual may be 
treated after one month. No recurrence has been 
observed (both BCC and keloid) during the follow-up of 
more than three years. 
 
        (A) 
 
        (B) 
 
        (C) 
    Pre-treatment    Post-treatment  
Figure 2: (A) A 60 y/F c/o pigmented lesion over dorsum of nose for the last 5 years, biopsy showed BCC. Re-188 patch (0.75 
mCi/cm2) was applied on alternate days. No recurrence was observed till one year post therapy. 
(B) A 23 y/M c/o spontaneously developed multiple keloids on his back. Re-188 patch was applied. Re-188 patch (0.5 mCi/cm2) 
was applied on Day 1 and Day 3. All lesions were flattened with decoloration. 
(C) A 23 Y/M h/o stretch injury for the last 10 years. Re-188 patch was applied. Significant depression in lesion elevation was 
noted after 5 month post therapy. 
 
Figure 3: 45 Y/M  with multople keloids all over the chest, abdomen and shoulders for the last 20 yrs. Multiple sessions of cryo 
and steroid therapy have been given with temporary relief. Patient was treated with Re-188 patch application on lesions. 
Images: (a) pre Re-188 patch application; (b) one month Re-188 patch application; (c) 3 months post Re-188 patch application. 
Patient is free from pain, itch and pruritus. The elevation in big lesions is reduced; small  lesions are flattened . Decoloration is 
observed.  
112    International Journal of Nuclear Medicine Research, 2017 Shukla and Mittal 
General Precautions 
To avoid leakage or leaching of radionuclide, the 
stability of the particles and lamination of patch is done 
before patch application. It will help in safe handling by 
personnel involved in the application of the patch to the 
patients. The radiation dermatitis may occur if the patch 
is mis-fit to the lesion or displaced during therapy 
period. 
SALIENT FEATURES OF RE-188 PATCH THERAPY  
The measurement of activity and the preparation of 
patch with 188Re is simple. The 188Re patch therapy has 
many advantages – 1) multiple lesions can be treated 
at a time, 2) the treatment of lesions where excision or 
external radiotherapy is not possible, 3) short tissue 
penetration and high linear energy transfer spares the 
radiation damage to underlying bone and soft tissue, 4) 
patients convenience is considered due to the 
presence of in-house generator. 
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